User menu

The use of chemotherapy regimens carrying a moderate or high risk of febrile neutropenia and the corresponding management of febrile neutropenia : an expert survey in breast cancer and non-Hodgkin's lymphoma

Bibliographic reference Gerlier, Laetitia ; Lamotte, Mark ; Awada, Ahmad ; Bosly, André ; Bries, Greet ; et. al. The use of chemotherapy regimens carrying a moderate or high risk of febrile neutropenia and the corresponding management of febrile neutropenia : an expert survey in breast cancer and non-Hodgkin's lymphoma. In: BMC Cancer, Vol. 10, p. 642 [1-10] (2010)
Permanent URL
  1. Caggiano Vincent, Weiss Richard V., Rickert Timothy S., Linde-Zwirble Walter T., Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy, 10.1002/cncr.20983
  2. Kuderer Nicole M., Dale David C., Crawford Jeffrey, Cosler Leon E., Lyman Gary H., Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients, 10.1002/cncr.21847
  3. Lyman GH, Michels SL, Reynolds MW, Barron R, Tomic KS, Yu J: Risk of mortality in patients with cancer who experience febrile neutropenia. Cancer. 2010
  4. Bosly A., , Bron D., Van Hoof A., De Bock R., Berneman Z., Ferrant A., Kaufman L., Dauwe M., Verhoef G., Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP, 10.1007/s00277-007-0399-y
  5. Pettengell Ruth, Schwenkglenks Matthias, Leonard Robert, Bosly André, Paridaens Robert, Constenla Manuel, Szucs Thomas D., Jackisch Christian, , Neutropenia occurrence and predictors of reduced chemotherapy delivery: results from the INC-EU prospective observational European neutropenia study, 10.1007/s00520-008-0430-4
  6. Fortner Barry V, Stepanski Edward J, Wang Stephanie C, Kasprowicz Sarah, Durrence H.Heith, Sleep and Quality of Life in Breast Cancer Patients, 10.1016/s0885-3924(02)00500-6
  7. Okon T, Fortner B, Schwartzberg I, Tauer KT, Durrence H, Kovacs A, Wheetly K, Woods C, Taylor D, Houts AC: Quality of life (QOL) in patients with grade IV chemotherapy-induced neutropenia (CIN). Proc Am Soc Clin Oncol. 2002, 21: Abstract 2920:275b.
  8. Kuderer Nicole M., Dale David C., Crawford Jeffrey, Lyman Gary H., Impact of Primary Prophylaxis With Granulocyte Colony-Stimulating Factor on Febrile Neutropenia and Mortality in Adult Cancer Patients Receiving Chemotherapy: A Systematic Review, 10.1200/jco.2006.08.8823
  9. Lyman Gary H., Morrison Vicki A., Dale David C., Crawford Jeffrey, Delgado David J., Fridman Moshe, Risk of Febrile Neutropenia among Patients with Intermediate-grade non-Hodgkin's Lymphoma Receiving CHOP Chemotherapy, 10.1080/1042819031000119262
  10. Lyman Gary H., Dale David C., Friedberg Jonathan, Crawford Jeffrey, Fisher Richard I., Incidence and Predictors of Low Chemotherapy Dose-Intensity in Aggressive Non-Hodgkin's Lymphoma: A Nationwide Study, 10.1200/jco.2004.03.213
  11. Vogel Charles L., Wojtukiewicz Marek Z., Carroll Robert R., Tjulandin Sergei A., Barajas-Figueroa Luis Javier, Wiens Brian L., Neumann Theresa A., Schwartzberg Lee S., First and Subsequent Cycle Use of Pegfilgrastim Prevents Febrile Neutropenia in Patients With Breast Cancer: A Multicenter, Double-Blind, Placebo-Controlled Phase III Study, 10.1200/jco.2005.09.102
  12. Crawford J, Wolff D, Culakova E, Poniewierski MS, Selby C, Dale D, Lyman GH for the ANC Study Group: First cycle risk of severe and febrile neutropenia in cancer patients receiving systemic chemotherapy: results from a prospective nationwide study. J Support Oncol. 2005, 3: 52-53.
  13. Martín M., Lluch A., Seguí M. A., Ruiz A., Ramos M., Adrover E., Rodríguez-Lescure Á., Grosse R., Calvo L., Fernandez-Chacón C., Roset M., Antón A., Isla D., del Prado P. Martínez, Iglesias L., Zaluski J., Arcusa A., López-Vega J. M., Muñoz M., Mel J. R., Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen, 10.1093/annonc/mdl135
  14. Chang J, Chemotherapy dose reduction and delay in clinical practice, 10.1016/s0959-8049(99)00259-2
  15. Smith Thomas J., Khatcheressian James, Lyman Gary H., Ozer Howard, Armitage James O., Balducci Lodovico, Bennett Charles L., Cantor Scott B., Crawford Jeffrey, Cross Scott J., Demetri George, Desch Christopher E., Pizzo Philip A., Schiffer Charles A., Schwartzberg Lee, Somerfield Mark R., Somlo George, Wade James C., Wade James L., Winn Rodger J., Wozniak Antoinette J., Wolff Antonio C., 2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice Guideline, 10.1200/jco.2006.06.4451
  16. Aapro M.S., Cameron D.A., Pettengell R., Bohlius J., Crawford J., Ellis M., Kearney N., Lyman G.H., Tjan-Heijnen V.C., Walewski J., Weber D.C., Zielinski C., EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours, 10.1016/j.ejca.2006.05.002
  17. Greil R., Psenak O., Roila F., , Hematopoietic growth factors: ESMO Recommendations for the applications, 10.1093/annonc/mdn107
  18. Pettengell Ruth, Bosly André, Szucs Thomas D., Jackisch Christian, Leonard Robert, Paridaens Robert, Constenla Manuel, Schwenkglenks Matthias, , Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INC-EU Prospective Observational European Neutropenia Study, 10.1111/j.1365-2141.2008.07514.x
  19. Schwenkglenks Matthias, Jackisch Christian, Constenla Manuel, Kerger Joseph N., Paridaens Robert, Auerbach Leo, Bosly André, Pettengell Ruth, Szucs Thomas D., Leonard Robert, Neutropenic event risk and impaired chemotherapy delivery in six European audits of breast cancer treatment, 10.1007/s00520-006-0034-9
  20. A Predictive Model for Aggressive Non-Hodgkin's Lymphoma, 10.1056/nejm199309303291402
  21. Armitage J. O., Staging Non-Hodgkin Lymphoma, 10.3322/canjclin.55.6.368
  22. Doorduijn J.K., van der Holt B., van Imhoff G.W., van der Hem K.G., Kramer M.H.H., van Oers M.H.J., Ossenkoppele G.J., Schaafsma M.R., Verdonck L.F., Verhoef G.E.G., Steijaert M.M.C., Buijt I., Uyl-de Groot C.A., van Agthoven M., Mulder A.H., Sonneveld P., CHOP Compared With CHOP Plus Granulocyte Colony-Stimulating Factor in Elderly Patients With Aggressive Non-Hodgkin’s Lymphoma, 10.1200/jco.2003.01.076
  23. Eldar-Lissai Adi, Cosler Leon E., Culakova Eva, Lyman Gary H., Economic Analysis of Prophylactic Pegfilgrastim in Adult Cancer Patients Receiving Chemotherapy, 10.1111/j.1524-4733.2007.00242.x
  24. ANNEMANS L., VAN OVERBEKE N., STANDAERT B., VAN BELLE S., Estimating resource use and cost of prophylactic management of neutropenia with filgrastim, 10.1111/j.1365-2834.2005.00550.x
  25. Pascoe Jennifer, Steven Neil, Antibiotics for the prevention of febrile neutropenia : , 10.1097/moh.0b013e32831ac543